NCT00092417View on ClinicalTrials.gov

Evaluation of the Safety and Tolerability of a Higher Potency Dose of an Investigational Vaccine Among Adults 50 Years of Age and Older (V211-009)

PHASE3CompletedINTERVENTIONAL

Enrollment

695

Participants

Timeline

Start Date

October 31, 2003

Primary Completion Date

June 30, 2004

Study Completion Date

June 30, 2004

Conditions

Healthy

Interventions

BIOLOGICAL

Comparator: Varicella Zoster Virus Vaccine

Single 0.65 mL subcutaneous injection of higher potency zoster vaccine (\~207,000 plaque-forming units \[PFU\]/0.65-mL dose)

BIOLOGICAL

Comparator: Varicella Zoster Virus Vaccine

Single 0.65 mL subcutaneous injection of lower potency zoster vaccine (\~58,000 plaque-forming units \[PFU\]/0.65-mL dose)

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00092417 - Evaluation of the Safety and Tolerability of a Higher Potency Dose of an Investigational Vaccine Among Adults 50 Years of Age and Older (V211-009) | Biotech Hunter | Biotech Hunter